Barclays Boosts LivaNova (NASDAQ:LIVN) Price Target to $73.00

LivaNova (NASDAQ:LIVN) had its target price raised by stock analysts at Barclays from $67.00 to $73.00 in a report released on Friday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Barclays‘s target price would indicate a potential upside of 3.40% from the stock’s current price.

Several other equities research analysts have also recently issued reports on LIVN. Robert W. Baird set a $75.00 price objective on shares of LivaNova in a research report on Tuesday, December 16th. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. The Goldman Sachs Group restated a “neutral” rating and set a $66.00 price target on shares of LivaNova in a report on Friday, January 9th. Stifel Nicolaus set a $80.00 price objective on LivaNova in a report on Wednesday. Finally, Mizuho increased their price objective on LivaNova from $70.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $74.78.

LivaNova Stock Performance

NASDAQ LIVN opened at $70.60 on Friday. The stock’s fifty day moving average is $64.74 and its two-hundred day moving average is $59.10. The firm has a market capitalization of $3.86 billion, a P/E ratio of -15.83 and a beta of 0.97. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.12 and a current ratio of 1.36. LivaNova has a fifty-two week low of $32.48 and a fifty-two week high of $71.92.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.80 by $0.06. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The business had revenue of $360.86 million during the quarter, compared to the consensus estimate of $354.31 million. During the same period last year, the company earned $0.81 EPS. The company’s revenue for the quarter was up 12.2% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. On average, research analysts anticipate that LivaNova will post 2.85 earnings per share for the current year.

Institutional Trading of LivaNova

Several institutional investors have recently added to or reduced their stakes in LIVN. Artisan Partners Limited Partnership lifted its stake in LivaNova by 94.5% during the third quarter. Artisan Partners Limited Partnership now owns 2,427,045 shares of the company’s stock worth $127,129,000 after purchasing an additional 1,179,436 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of LivaNova by 83.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after buying an additional 1,067,349 shares during the period. Invesco Ltd. raised its holdings in shares of LivaNova by 714.7% in the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock valued at $46,313,000 after buying an additional 902,447 shares during the period. Scopia Capital Management LP acquired a new position in LivaNova during the 2nd quarter worth about $36,657,000. Finally, Millennium Management LLC lifted its stake in LivaNova by 22.4% during the 3rd quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock worth $155,559,000 after acquiring an additional 544,033 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.